3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
28
Carcinoma, Renal Cell
19
Carcinoma, Non-Small-Cell Lung
13
Carcinoma, Hepatocellular
10
Brain Neoplasms
7
Skin Neoplasms
6
Neoplasm Metastasis
6
Clear-cell metastatic renal cell carcinoma
6
Neoplasms
5
Kidney Neoplasms
5
Colorectal Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Pancreatic Neoplasms
4
Lung Neoplasms
4
Carcinoma, Transitional Cell
4
Triple Negative Breast Neoplasms
3
Multiple Myeloma
3
Mesothelioma
3
Liver Neoplasms
3
Breast Neoplasms
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma
2
Recurrence
2
Prostatic Neoplasms
2
Mesothelioma, Malignant
2
Lymphoma, Non-Hodgkin
2
Glioblastoma
2
Colonic Neoplasms
2
Interventions
penpulimab
1
niraparib
1
anlotinib
1
Taxes
1
Ipilimumab
1
IFL protocol
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pancreatic Adenocarcinoma Metastatic
×
Ipilimumab
×
Clear all
NCT06747845
2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
68 enrolled